Table 6.
Reported adverse events possibly attributable to pharmacological interventions to prevent or delay type 2 diabetes. Numbers are percentages except where indicated
| Active intervention and trial | Event | Intervention group | Placebo group |
|---|---|---|---|
| Acarbose | |||
| Fang, 2004w19 | Gastrointestinal side effects | 8.0 | 0.0 |
| Pan, 2003w31 | Gastrointestinal side effects | 35.7 | 18.2 |
| STOP-NIDDM, 2002w33 | Gastrointestinal side effects | 13.0 | 2.5 |
| Flumamine | |||
| Fang, 2004w19 | Gastrointestinal side effects | 6.3 | 0.0 |
| Glipizide | |||
| Eriksson, 2006w38 | Hypoglycaemic symptoms | 41.0 | 32.0 |
| Troglitazone | |||
| DPP, 2005w1 | Liver function test ≥3 | 4.3 | 3.6 |
| Liver function test ≥10 | 1.2 | 0.2 | |
| Metformin | |||
| DPP, 2002w23 | Gastrointestinal symptoms | 77.8* | 30.7* |
| IDDP, 2004w39 | Hypoglycaemia | 8.4 | 0.0 |
| Gastrointestinal symptoms | 1.9 | 0.0 | |
| Li, 1999w30 | Gastrointestinal side effects | 4.4 | 0.0 |
| Orlistat | |||
| XENDOS, 2004w37 | At least one gastrointestinal event in 1st year | 91.0 | 65.0 |
| At least one gastrointestinal event in 4th year | 36.0 | 23.0 | |
| Withdrawals because of adverse events | 4.0 | 8.0 | |
*Number of events per 100 person years.